Your browser of choice has not been tested for use with If you have issues, please download one of the browsers listed here.

Inovio Pharma (INO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
QIAGEN Partners Inovio to Develop Companion Diagnostics

QIAGEN's (QGEN) Sample to Insight workflows and expertise in developing diagnostic solutions will aptly compliment Inovio regarding Precision Medicine in immuno-oncology.

MASI : 138.97 (+0.91%)
QGEN : 38.20 (-0.65%)
INO : 3.26 (+0.31%)
CNMD : 81.43 (+0.54%)
Inovio and QIAGEN Establish Collaboration to Develop Diagnostic Test for VGX-3100, Inovio's Novel Immunotherapy Targeting Advanced Cervical Pre-Cancer

Inovio Pharmaceuticals Inc. (NASDAQ: INO) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration to co-develop a diagnostic test to identify patients most likely to...

INO : 3.26 (+0.31%)
QIAGEN and Inovio Collaborate to Develop Companion Diagnostic for Novel Immunotherapy Targeting Precancerous Cervical Lesions

QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) and Inovio Pharmaceuticals Inc. (NASDAQ:INO) today announced a collaboration to co-develop a companion diagnostic to guide clinical decision-making...

QGEN : 38.20 (-0.65%)
INO : 3.26 (+0.31%)
Inovio and Plumbline Life Sciences Establish Animal Health Collaboration to Develop A Novel Vaccine Against Deadly African Swine Fever Virus

Inovio Pharmaceuticals Inc. (NASDAQ: INO) and Plumbline Life Sciences (XKRX: 222670) today announced a collaboration to co-develop a novel animal health vaccine for African swine fever (ASF) virus. The...

INO : 3.26 (+0.31%)
Inovio (INO) Q1 Earnings & Revenues Fall Short of Estimates

Inovio Pharmaceuticals' (INO) earnings and revenues disappoint with an estimate miss in the first quarter. Shares slip in after-hours trading.

AZN : 39.02 (+0.93%)
INO : 3.26 (+0.31%)
REGN : 312.56 (-0.86%)
SNY : 42.28 (+0.40%)
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Misses Revenue Estimates

Inovio (INO) delivered earnings and revenue surprises of -3.45% and -36.25%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

INO : 3.26 (+0.31%)
Inovio: 1Q Earnings Snapshot

PLYMOUTH MEETING, Pa. (AP) _ Inovio Pharmaceuticals Inc. (INO) on Thursday reported a loss of $29.2 million in its first quarter.

INO : 3.26 (+0.31%)
Inovio Pharmaceuticals Reports 2019 First Quarter Financial Results

Inovio Pharmaceuticals, Inc. (NASDAQ: INO), an innovative biotechnology company focused on the discovery, development and commercialization of its synthetic nucleic technology targeted against cancers...

INO : 3.26 (+0.31%)
What's in the Cards for AcelRx (ACRX) This Earnings Season?

We expect AcelRx (ACRX) to provide update on the launch of its newly approved drug DSUVIA, when it reports first-quarter 2019 results.

GNMSF : 182.8100 (+0.86%)
HZNP : 24.83 (+0.93%)
ACRX : 2.74 (-2.14%)
INO : 3.26 (+0.31%)
What's in Cards for Cumberland (CPIX) This Earnings Season?

Cumberland (CPIX) will provide updates on pipeline candidates with the release of its first-quarter 2019 results.

CPIX : 6.40 (unch)
GNMSF : 182.8100 (+0.86%)
HZNP : 24.83 (+0.93%)
INO : 3.26 (+0.31%)
What's in the Cards for Corbus (CRBP) This Earnings Season?

Corbus (CRBP) will provide updates on its lead candidate lenabasum, when it releases first-quarter 2019 results.

CRBP : 7.30 (+0.41%)
GNMSF : 182.8100 (+0.86%)
HZNP : 24.83 (+0.93%)
INO : 3.26 (+0.31%)
Inovio Receives European Medicines Agency Certification For Quality and Non-Clinical Data for Its Phase 3 Product, VGX-3100

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that its lead Phase 3 product candidate, VGX-3100, has been granted an Advanced Therapy Medicinal Product Certificate for quality and non-clinical...

INO : 3.26 (+0.31%)
Protalix (PLX) to Report Q1 Earnings: What's in the Cards?

Protalix (PLX) is scheduled to release its first quarter 2019 results on May 6 and we expect the company to provide updates on the pipeline.

RARE : 57.18 (+0.97%)
INO : 3.26 (+0.31%)
AMGN : 171.28 (-0.48%)
PLX : 0.39 (-2.69%)
Inovio's Phase 3 HPV Immunotherapy Selected As "Best Therapeutic Vaccine" at World Vaccine Congress

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that VGX-3100, its Phase 3 immunotherapy to treat cervical dysplasia, was recognized as "Best Therapeutic Vaccine" at the World Vaccine Congress...

INO : 3.26 (+0.31%)
New Research: Key Drivers of Growth for Zillow Group, Genpact, Royal Caribbean Cruises, CommScope Holding, Inovio Pharmaceuticals, and E.W. Scripps -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Zillow Group, Inc. (NASDAQ:Z), Genpact...

SSP : 15.66 (-0.38%)
COMM : 17.45 (-0.23%)
G : 36.08 (+0.22%)
Z : 41.86 (+0.84%)
RCL : 123.68 (-0.59%)
INO : 3.26 (+0.31%)
ZG : 41.36 (+0.63%)
Inovio (INO) Up 10.7% Since Last Earnings Report: Can It Continue?

Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

INO : 3.26 (+0.31%)
Inovio Earns 3rd Milestone Fee From AstraZeneca for MEDI0457

Inovio (INO) receives the third milestone payment from AstraZeneca post the initiation of dosing in a phase II combo study of the latter's MEDI0457 for HPV related anal, penile and vulvar cancers.

PDLI : 2.96 (-0.67%)
AZN : 39.02 (+0.93%)
INO : 3.26 (+0.31%)
KMDA : 5.68 (-0.18%)
Biotech Brief: Growing Number of Ongoing Clinical Trials for Leukemia (AML) Brings New Hope

In the last few years the number of clinical trials looking for new treatments for Leukemia (AML) has continued to grow. In 2017, a report from ManagedCare said that: "… There are over 400 phase 2 or...

CHRS : 20.36 (unch)
CVM : 4.74 (+3.27%)
INO : 3.26 (+0.31%)
INSM : 26.33 (+1.98%)
MBRX : 1.11 (-0.89%)
Inovio Achieves Third Cancer Indication Milestone for MEDI0457 Phase 2 Development

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it achieved a third indication milestone from AstraZeneca resulting from dosing a patient in a Phase 2 combination trial evaluating MEDI0457...

INO : 3.26 (+0.31%)
Inovio's HPV Candidate Shows Efficacy in Pilot Study, Stock Up

Inovio's (INO) investigational HPV therapy, INO-3106, achieves the clinical efficacy for treating patients with recurrent respiratory papillomatosis, an HPV-associated disease. Shares up.

AZN : 39.02 (+0.93%)
INO : 3.26 (+0.31%)
RHHBY : 34.0000 (+0.74%)
REGN : 312.56 (-0.86%)

Van Meerten Stock Picks

NextEra Energy - Large Cap Pick
The Large Cap Pick of the Day is electric utility company NextEra Energy(NEE).
NEE -0.16
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar